SCMP - Sucampo Pharmaceuticals Stock Price, News & Analysis

$10.35 0.00 (0.00 %)
(As of 11/22/2017 04:00 PM ET)
Previous Close$10.35
Today's Range$10.25 - $10.50
52-Week Range$9.30 - $17.55
Volume386,400 shs
Average Volume645,840 shs
Market Capitalization$482.69 million
P/E Ratio7.09
Dividend YieldN/A
Beta1.38

About Sucampo Pharmaceuticals (NASDAQ:SCMP)

Sucampo Pharmaceuticals logoSucampo Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of pharmaceutical products. Its primary focus areas are gastroenterology, ophthalmology and oncology-related disorders. Its product candidates include VTS-270, Lubiprostone (AMITIZA), Unoprostone is opropyl (RESCULA) and CPP-1X/sulindac combination product. VTS-270 is an investigational drug under clinical study for the treatment of Niemann-Pick Disease Type C-1, an ultra-orphan, progressive and fatal disease. AMITIZA is a ClC-2 chloride channel activator, which has been approved for three indications that cover distinct patient types: chronic idiopathic constipation, irritable bowel syndrome with constipation, and opioid-induced constipation. RESCULA is a Big Potassium channel activator used to lower intraocular pressure. CPP-1X/sulindac combination product is meant for the treatment of familial adenomatous polyposis (FAP).


Industry, Sector and Symbol:
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: Pharmaceuticals
  • Sector: Healthcare
  • Symbol: NASDAQ:SCMP
  • CUSIP: 86490910
  • Web: www.sucampo.com
Debt:
  • Debt-to-Equity Ratio: 7.37%
  • Current Ratio: 5.11%
  • Quick Ratio: 4.46%
Price-To-Earnings:
  • Trailing P/E Ratio: 7.09
  • Forward P/E Ratio: 9.24
  • P/E Growth: 3.08
Sales & Book Value:
  • Annual Sales: $230.06 million
  • Price / Sales: 2.10
  • Cash Flow: $2.41 per share
  • Price / Cash: 4.29
  • Book Value: $0.85 per share
  • Price / Book: 12.18
Profitability:
  • Trailing EPS: ($3.32)
  • Net Income: $18.48 million
  • Net Margins: -60.24%
  • Return on Equity: 74.58%
  • Return on Assets: 16.85%
Misc:
  • Employees: 139
  • Outstanding Shares: 46,640,000
 

Frequently Asked Questions for Sucampo Pharmaceuticals (NASDAQ:SCMP)

What is Sucampo Pharmaceuticals' stock symbol?

Sucampo Pharmaceuticals trades on the NASDAQ under the ticker symbol "SCMP."

How were Sucampo Pharmaceuticals' earnings last quarter?

Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) announced its quarterly earnings data on Wednesday, November, 1st. The biopharmaceutical company reported $0.27 earnings per share for the quarter, topping the Zacks' consensus estimate of $0.25 by $0.02. The biopharmaceutical company earned $61.27 million during the quarter, compared to analyst estimates of $58.05 million. Sucampo Pharmaceuticals had a negative net margin of 60.24% and a positive return on equity of 74.58%. The business's quarterly revenue was up 5.9% on a year-over-year basis. During the same period in the previous year, the business posted $0.30 EPS. View Sucampo Pharmaceuticals' Earnings History.

What guidance has Sucampo Pharmaceuticals issued on next quarter's earnings?

Sucampo Pharmaceuticals issued an update on its FY17 earnings guidance on Wednesday, November, 1st. The company provided earnings per share (EPS) guidance of $1.10-1.15 for the period, compared to the Thomson Reuters consensus EPS estimate of $1.01. The company issued revenue guidance of $250-255 million, compared to the consensus revenue estimate of $234.49 million.

Where is Sucampo Pharmaceuticals' stock going? Where will Sucampo Pharmaceuticals' stock price be in 2017?

7 brokers have issued twelve-month price targets for Sucampo Pharmaceuticals' shares. Their predictions range from $11.00 to $30.00. On average, they anticipate Sucampo Pharmaceuticals' share price to reach $17.14 in the next twelve months. View Analyst Ratings for Sucampo Pharmaceuticals.

What are Wall Street analysts saying about Sucampo Pharmaceuticals stock?

Here are some recent quotes from research analysts about Sucampo Pharmaceuticals stock:

  • 1. According to Zacks Investment Research, "Sucampo is focused on expanding Amitiza’s label and penetrating new markets. Also, Sucampo’s collaborations with firms like Takeda and Mylan for Amitiza’s commercialization is a big positive. Also, through the agreement with Cancer Prevention Pharmaceuticals, Sucampo acquired an exclusive option to develop and commercialize its combination, CPP-1X/sulindac, in North America. Moreover, the Vtesse acquisition added a pivotal program in Niemann-Pick Disease type C1 to its pipeline. However, dependence of Sucampo on Amitiza for growth is concerning with few companies trying to market and sell generic version of Amitiza. A decline in Amitiza's sales will adversely impact the top line. Moreover, it had its share of pipeline setbacks. Shares of the company have underperformed the industry. Estimates have remained stable ahead of the Q3 earnings results. The company has a mixed record of earnings surprises in the recent quarters." (10/17/2017)
  • 2. Maxim Group analysts commented, "Sucampo has acquired privately owned Vtesse Inc. and its lead orphan drug candidate for Niemann-Pick Type C1, VTS-270, for $170M in cash & the rest in stock: total of $200M. There is also a contingent earn-out (payments in the mid-single digit to double-digit royalties on global net sales) of the product at increasing net sales levels." (4/3/2017)
  • 3. Jefferies Group LLC analysts commented, "Post the Q4 results and guidance we have revisited our assumptions and are making two changes to our model reflecting ' 1) likely Amitiza mandated price erosion in Japan and 2) our switch projections for the alternative formulation of Amitiza. We also fine-tune our FY17 revs and EPS estimates. We continue to view potential business development/M&A as critical to the longer term outlook given the finite life of Amitiza and await mgt's plans." (3/17/2017)
  • 4. Mizuho analysts commented, "We reiterate our Buy rating and $16 PT into the 4Q:16 print on March 8. The near-term Amitiza outlook remains favorable in both the U.S. and Japanese markets, which we believe may support additional optionality for the company in front of its 2021 patent cliff." (3/6/2017)

Who are some of Sucampo Pharmaceuticals' key competitors?

Who are Sucampo Pharmaceuticals' key executives?

Sucampo Pharmaceuticals' management team includes the folowing people:

  • Peter S. Greenleaf, Chairman of the Board, Chief Executive Officer (Age 47)
  • Peter P. Pfreundschuh CPA, Chief Financial Officer (Age 48)
  • Max Donley, Executive Vice President of Global Human Resources, Information Technology and Strategy (Age 48)
  • Matthias Alder, Executive Vice President (Age 52)
  • Peter A. Kiener Ph.D., Chief Scientific Officer (Age 64)
  • Alex Driggs, General Counsel, Corporate Secretary (Age 41)
  • Peter Lichtlen M.D., Ph.D., Chief Medical Officer (Age 47)
  • John H. Johnson, Lead Independent Director (Age 59)
  • Paul R. Edick, Director (Age 62)
  • Daniel P. Getman Ph.D., Director (Age 59)

Who owns Sucampo Pharmaceuticals stock?

Sucampo Pharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Point72 Asset Management L.P. (4.00%), Dimensional Fund Advisors LP (3.19%), Royce & Associates LP (2.51%), Bank of New York Mellon Corp (0.89%), Prudential Financial Inc. (0.89%) and Schwab Charles Investment Management Inc. (0.63%). Company insiders that own Sucampo Pharmaceuticals stock include Andrew P Smith, Daniel P Getman, Jason Patrick Meyenburg, Jones W Bryan, Matthias Alder, Peter Greenleaf and Sachiko Kuno. View Institutional Ownership Trends for Sucampo Pharmaceuticals.

Who sold Sucampo Pharmaceuticals stock? Who is selling Sucampo Pharmaceuticals stock?

Sucampo Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Rubric Capital Management LP, Dimensional Fund Advisors LP, Cornerstone Capital Management Holdings LLC., Systematic Financial Management LP, Stevens Capital Management LP, OxFORD Asset Management LLP, Strs Ohio and Public Employees Retirement System of Ohio. Company insiders that have sold Sucampo Pharmaceuticals company stock in the last year include Daniel P Getman, Matthias Alder, Peter Greenleaf and Sachiko Kuno. View Insider Buying and Selling for Sucampo Pharmaceuticals.

Who bought Sucampo Pharmaceuticals stock? Who is buying Sucampo Pharmaceuticals stock?

Sucampo Pharmaceuticals' stock was purchased by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., Prudential Financial Inc., Royce & Associates LP, GSA Capital Partners LLP, Argent Capital Management LLC, Ameriprise Financial Inc., Cadence Capital Management LLC and Dupont Capital Management Corp. Company insiders that have bought Sucampo Pharmaceuticals stock in the last two years include Jason Patrick Meyenburg and Jones W Bryan. View Insider Buying and Selling for Sucampo Pharmaceuticals.

How do I buy Sucampo Pharmaceuticals stock?

Shares of Sucampo Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Sucampo Pharmaceuticals' stock price today?

One share of Sucampo Pharmaceuticals stock can currently be purchased for approximately $10.35.

How big of a company is Sucampo Pharmaceuticals?

Sucampo Pharmaceuticals has a market capitalization of $482.69 million and generates $230.06 million in revenue each year. The biopharmaceutical company earns $18.48 million in net income (profit) each year or ($3.32) on an earnings per share basis. Sucampo Pharmaceuticals employs 139 workers across the globe.

How can I contact Sucampo Pharmaceuticals?

Sucampo Pharmaceuticals' mailing address is 805 King Farm Blvd Ste 550, ROCKVILLE, MD 20850-6162, United States. The biopharmaceutical company can be reached via phone at +1-301-9613400 or via email at [email protected]


MarketBeat Community Rating for Sucampo Pharmaceuticals (SCMP)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  239 (Vote Outperform)
Underperform Votes:  193 (Vote Underperform)
Total Votes:  432
MarketBeat's community ratings are surveys of what our community members think about Sucampo Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Analysts' Consensus Rating for Sucampo Pharmaceuticals (NASDAQ:SCMP)

  (How are Consensus Ratings Calculated?)
Ratings Breakdown: 0 Sell Ratings, 2 Hold Ratings, 5 Buy Ratings, 0 Strong Buy Ratings
Consensus Rating:Buy (Score: 2.71)
Consensus Price Target: $17.14 (65.63% upside)

Consensus Price Target History for Sucampo Pharmaceuticals (NASDAQ:SCMP)

Price Target History for Sucampo Pharmaceuticals (NASDAQ:SCMP)

Analysts' Ratings History for Sucampo Pharmaceuticals (NASDAQ:SCMP)

Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
11/14/2017B. RileyInitiated CoverageBuy -> Buy$14.00N/AView Rating Details
11/2/2017Maxim GroupReiterated RatingBuy$23.00N/AView Rating Details
11/1/2017MizuhoReiterated RatingHold$12.00N/AView Rating Details
8/21/2017Leerink SwannInitiated CoverageMarket Perform -> Outperform$14.00 -> $15.00HighView Rating Details
8/3/2017Roth CapitalSet Price TargetBuy$30.00MediumView Rating Details
5/4/2017Jefferies Group LLCLower Price TargetHold$13.00 -> $11.00MediumView Rating Details
3/10/2017WallachBeth CapitalLower Price TargetBuy$20.00 -> $15.00LowView Rating Details
9/7/2016Northland SecuritiesInitiated CoverageOutperform$15.00N/AView Rating Details
5/4/2016GuggenheimReiterated RatingBuy$29.00N/AView Rating Details
(Data available from 11/22/2015 forward)

Earnings

Earnings History and Estimates Chart for Sucampo Pharmaceuticals (NASDAQ:SCMP)

Earnings by Quarter for Sucampo Pharmaceuticals (NASDAQ:SCMP)

Earnings History by Quarter for Sucampo Pharmaceuticals (NASDAQ SCMP)

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/1/2017Q3 2017$0.25$0.27$58.05 million$61.27 millionViewN/AView Earnings Details
8/2/2017Q2 2017$0.22$0.28$56.44 million$59.90 millionViewListenView Earnings Details
5/3/2017Q1 2017$0.28$0.23$54.15 million$56.30 millionViewListenView Earnings Details
3/8/2017Q4 2016$0.48$0.68$66.00 million$73.00 millionViewListenView Earnings Details
11/9/2016Q316$0.26$0.28$51.30 million$57.90 millionViewListenView Earnings Details
8/3/2016Q216$0.22$0.23$48.33 million$52.00 millionViewListenView Earnings Details
5/4/2016Q116$0.19$0.21$44.11 million$47.20 millionViewListenView Earnings Details
3/8/2016Q415$0.19$0.43$42.72 million$55.40 millionViewListenView Earnings Details
11/4/2015Q315$0.18$0.16$36.18 million$33.50 millionViewListenView Earnings Details
8/5/2015Q215$0.15$0.21$31.90 million$34.90 millionViewListenView Earnings Details
5/6/2015Q114$0.14$0.14$30.19 million$29.50 millionViewListenView Earnings Details
3/4/2015Q413$0.17$0.21$37.23 million$37.80 millionViewListenView Earnings Details
11/6/2014Q313$0.04$0.03$26.11 million$31.50 millionViewListenView Earnings Details
8/5/2014Q213$0.03$0.04$24.06 million$24.10 millionViewListenView Earnings Details
5/7/2014Q113$0.04$0.02$24.19 million$22.20 millionViewListenView Earnings Details
2/26/2014Q4($0.04)$0.06$22.75 million$24.50 millionViewListenView Earnings Details
3/13/2013Q4 2012$0.12$0.32$32.21 million$34.90 millionViewListenView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Sucampo Pharmaceuticals (NASDAQ:SCMP)
2017 EPS Consensus Estimate: $1.05
2018 EPS Consensus Estimate: $1.15
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20173$0.23$0.29$0.25
Q2 20172$0.22$0.26$0.24
Q3 20172$0.23$0.27$0.25
Q4 20173$0.21$0.36$0.31
Q1 20181$0.26$0.26$0.26
Q2 20181$0.24$0.24$0.24
Q3 20181$0.28$0.28$0.28
Q4 20181$0.37$0.37$0.37
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Sucampo Pharmaceuticals (NASDAQ:SCMP)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Sucampo Pharmaceuticals (NASDAQ SCMP)

Insider Ownership Percentage: 4.13%
Institutional Ownership Percentage: 57.79%
Insider Trades by Quarter for Sucampo Pharmaceuticals (NASDAQ:SCMP)
Institutional Ownership by Quarter for Sucampo Pharmaceuticals (NASDAQ:SCMP)

Insider Trades by Quarter for Sucampo Pharmaceuticals (NASDAQ SCMP)

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/11/2017Sachiko KunoMajor ShareholderSell1,000,000$12.00$12,000,000.00View SEC Filing  
9/6/2017Jason Patrick MeyenburgInsiderBuy4,000$12.13$48,520.00View SEC Filing  
8/4/2017Jones W BryanInsiderBuy4,700$10.60$49,820.00View SEC Filing  
11/29/2016Daniel P GetmanDirectorSell20,000$16.86$337,200.00View SEC Filing  
11/29/2016Peter GreenleafCEOSell200,000$16.84$3,368,000.00View SEC Filing  
11/28/2016Matthias AlderEVPSell150,000$16.00$2,400,000.00View SEC Filing  
11/15/2016Andrew P SmithCFOSell1,766$15.58$27,514.28View SEC Filing  
8/28/2015Daniel P. GetmanDirectorSell30,000$28.14$844,200.00View SEC Filing  
7/20/2015Thomas J KnappInsiderSell64,528$23.43$1,511,891.04View SEC Filing  
3/12/2015William AshtonDirectorSell55,762$17.55$978,623.10View SEC Filing  
3/11/2015Anthony C CelesteDirectorSell65,966$17.34$1,143,850.44View SEC Filing  
12/16/2014Cary J ClaiborneCFOSell50,000$12.91$645,500.00View SEC Filing  
12/15/2014Cary J ClaiborneCFOSell7,100$12.89$91,519.00View SEC Filing  
8/7/2014Sachiko KunoMajor ShareholderSell181,727$6.28$1,141,245.56View SEC Filing  
8/4/2014Ryuji UenoMajor ShareholderSell140,873$6.02$848,055.46View SEC Filing  
7/31/2014S&R Technology Holdings, LlcMajor ShareholderSell100$6.25$625.00View SEC Filing  
7/30/2014S&R Technology Holdings, LlcMajor ShareholderSell300$6.25$1,875.00View SEC Filing  
7/25/2014Ryuji UenoMajor ShareholderSell16,155$6.26$101,130.30View SEC Filing  
7/23/2014Ryuji UenoMajor ShareholderSell5,845$6.29$36,765.05View SEC Filing  
7/22/2014S&R Technology Holdings, LlcMajor ShareholderSell2,500$6.25$15,625.00View SEC Filing  
7/21/2014S&R Technology Holdings, LlcMajor ShareholderSell100$6.25$625.00View SEC Filing  
7/18/2014S&R Technology Holdings, LlcMajor ShareholderSell15,000$6.27$94,050.00View SEC Filing  
4/29/2014S&R Technology Holdings, Llcmajor shareholderSell113,600$6.65$755,440.00View SEC Filing  
4/25/2014Sachiko Kunomajor shareholderSell118,700$6.69$794,103.00View SEC Filing  
3/18/2014Gayle DolecekDirectorSell1,200$8.03$9,636.00View SEC Filing  
2/27/2014Cary ClaiborneCFOSell2,500$9.00$22,500.00View SEC Filing  
1/17/2014Ryuji UenoCEOSell360,000$10.36$3,729,600.00View SEC Filing  
1/7/2014Cary ClaiborneCFOSell2,500$9.00$22,500.00View SEC Filing  
10/16/2013Sachiko KunoMajor ShareholderSell360,000$6.35$2,286,000.00View SEC Filing  
9/18/2013Ryuji UenoCEOSell38,462$5.69$218,848.78View SEC Filing  
9/3/2013Ryuji UenoCEOSell38,462$5.59$215,002.58View SEC Filing  
8/19/2013Ryuji UenoCEOSell38,462$6.04$232,310.48View SEC Filing  
8/6/2013Sachiko Kunomajor shareholderSell38,462$6.21$238,849.02View SEC Filing  
7/24/2013Ryuji UenoCEOSell38,462$6.52$250,772.24View SEC Filing  
7/9/2013S&R Technology Holdings, LlcMajor ShareholderSell38,462$6.48$249,233.76View SEC Filing  
6/24/2013S&R Technology Holdings, LlcMajor ShareholderSell38,462$6.61$254,233.82View SEC Filing  
6/10/2013Sachiko KunoMajor ShareholderSell38,462$7.29$280,387.98View SEC Filing  
5/28/2013Ryuji UenoCEOSell38,462$8.79$338,080.98View SEC Filing  
5/21/2013Cary J ClaiborneCFOSell4,640$9.52$44,172.80View SEC Filing  
5/20/2013Stanley G MieleSVPSell6,400$9.60$61,440.00View SEC Filing  
5/16/2013Stanley G MieleSVPSell48,600$9.67$469,962.00View SEC Filing  
5/15/2013Timothy I MaudlinDirectorBuy32,870$9.82$322,783.40View SEC Filing  
5/13/2013Sachiko KunoMajor ShareholderSell38,462$9.27$356,542.74View SEC Filing  
2/4/2013S&R Technology Holdings, LlcMajor ShareholderSell38,462$5.22$200,771.64View SEC Filing  
12/26/2012S&R Technology Holdings, LlcMajor ShareholderSell20,262$5.01$101,512.62View SEC Filing  
11/27/2012Sachiko KunoMajor ShareholderSell12,205$5.00$61,025.00View SEC Filing  
11/13/2012Sachiko KunoMajor ShareholderSell11,962$5.00$59,810.00View SEC Filing  
11/1/2012Sachiko KunoMajor ShareholderSell37,595$5.06$190,230.70View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Sucampo Pharmaceuticals (NASDAQ SCMP)

Source:
DateHeadline
Alnylams RNAi Candidate Gains Breakthrough Therapy Status - NasdaqAlnylam's RNAi Candidate Gains Breakthrough Therapy Status - Nasdaq
www.nasdaq.com - November 22 at 7:38 AM
Sucampo Pharmaceuticals Announces Webcast of Its Presentation at the 29th Annual Piper Jaffray Healthcare ConferenceSucampo Pharmaceuticals Announces Webcast of Its Presentation at the 29th Annual Piper Jaffray Healthcare Conference
finance.yahoo.com - November 22 at 7:38 AM
Roche Reports Positive Data From Tecentriq Combination StudyRoche Reports Positive Data From Tecentriq Combination Study
www.zacks.com - November 20 at 9:37 AM
Sucampo Pharmaceuticals, Inc. (SCMP) Now Covered by Analysts at Sucampo Pharmaceuticals, Inc. (SCMP) Now Covered by Analysts at
www.americanbankingnews.com - November 19 at 4:20 PM
Sucampo Pharmaceuticals, Inc. (SCMP) Expected to Earn FY2017 Earnings of $1.14 Per ShareSucampo Pharmaceuticals, Inc. (SCMP) Expected to Earn FY2017 Earnings of $1.14 Per Share
www.americanbankingnews.com - November 17 at 8:10 PM
Cardinal Health (CAH) to Divest Assets to Shanghai PharmaCardinal Health (CAH) to Divest Assets to Shanghai Pharma
finance.yahoo.com - November 15 at 8:20 AM
ETFs with exposure to Sucampo Pharmaceuticals, Inc. : November 13, 2017ETFs with exposure to Sucampo Pharmaceuticals, Inc. : November 13, 2017
finance.yahoo.com - November 14 at 7:44 AM
Sucampo to Host 2017 R&D Day on November 16 in New York - GlobeNewswire (press release)Sucampo to Host 2017 R&D Day on November 16 in New York - GlobeNewswire (press release)
globenewswire.com - November 9 at 6:08 PM
Sucampo to Host 2017 R&D Day on November 16 in New YorkSucampo to Host 2017 R&D Day on November 16 in New York
finance.yahoo.com - November 9 at 6:08 PM
 Analysts Expect Sucampo Pharmaceuticals, Inc. (SCMP) Will Announce Quarterly Sales of $76.41 Million Analysts Expect Sucampo Pharmaceuticals, Inc. (SCMP) Will Announce Quarterly Sales of $76.41 Million
www.americanbankingnews.com - November 8 at 2:14 PM
Sucampo Pharmaceuticals, Inc. (SCMP) Expected to Post Earnings of $0.28 Per ShareSucampo Pharmaceuticals, Inc. (SCMP) Expected to Post Earnings of $0.28 Per Share
www.americanbankingnews.com - November 6 at 3:24 AM
Sucampo Pharmaceuticals, Inc. (SCMP) Given Average Rating of "Buy" by AnalystsSucampo Pharmaceuticals, Inc. (SCMP) Given Average Rating of "Buy" by Analysts
www.americanbankingnews.com - November 6 at 3:24 AM
FY2017 EPS Estimates for Sucampo Pharmaceuticals, Inc. Lifted by Jefferies Group (SCMP)FY2017 EPS Estimates for Sucampo Pharmaceuticals, Inc. Lifted by Jefferies Group (SCMP)
www.americanbankingnews.com - November 6 at 2:54 AM
Sucampo Pharmaceuticals, Inc. (SCMP) Expected to Post FY2017 Earnings of $1.02 Per ShareSucampo Pharmaceuticals, Inc. (SCMP) Expected to Post FY2017 Earnings of $1.02 Per Share
www.americanbankingnews.com - November 6 at 2:54 AM
Sucampo (SCMP) Beats on Q3 Earnings & Revenues, Ups 17 ViewSucampo (SCMP) Beats on Q3 Earnings & Revenues, Ups '17 View
finance.yahoo.com - November 4 at 6:57 PM
Sucampo Pharmaceuticals, Inc. :SCMP-US: Earnings Analysis: Q3, 2017 By the Numbers : November 3, 2017Sucampo Pharmaceuticals, Inc. :SCMP-US: Earnings Analysis: Q3, 2017 By the Numbers : November 3, 2017
finance.yahoo.com - November 4 at 1:55 PM
Sucampo Pharmaceuticals, Inc. (SCMP) Issues Quarterly  Earnings Results, Beats Expectations By $0.02 EPSSucampo Pharmaceuticals, Inc. (SCMP) Issues Quarterly Earnings Results, Beats Expectations By $0.02 EPS
www.americanbankingnews.com - November 2 at 2:36 PM
ETFs with exposure to Sucampo Pharmaceuticals, Inc. : November 1, 2017ETFs with exposure to Sucampo Pharmaceuticals, Inc. : November 1, 2017
finance.yahoo.com - November 2 at 8:34 AM
Edited Transcript of SCMP earnings conference call or presentation 1-Nov-17 12:30pm GMTEdited Transcript of SCMP earnings conference call or presentation 1-Nov-17 12:30pm GMT
finance.yahoo.com - November 2 at 8:34 AM
Sucampo Pharmaceuticals, Inc. (SCMP) Earns "Hold" Rating from MizuhoSucampo Pharmaceuticals, Inc. (SCMP) Earns "Hold" Rating from Mizuho
www.americanbankingnews.com - November 1 at 10:24 PM
Sucampo Reports Third Quarter 2017 Financial Results - GlobeNewswire (press release)Sucampo Reports Third Quarter 2017 Financial Results - GlobeNewswire (press release)
globenewswire.com - November 1 at 8:30 AM
Sucampo Reports Third Quarter 2017 Financial ResultsSucampo Reports Third Quarter 2017 Financial Results
finance.yahoo.com - November 1 at 8:30 AM
Sucampo tops 3Q revenue forecastsSucampo tops 3Q revenue forecasts
finance.yahoo.com - November 1 at 8:30 AM
Sucampo Pharmaceuticals, Inc. Class A to Host Earnings CallSucampo Pharmaceuticals, Inc. Class A to Host Earnings Call
finance.yahoo.com - November 1 at 8:30 AM
Sucampo Pharmaceuticals, Inc. (SCMP) Scheduled to Post Quarterly Earnings on TuesdaySucampo Pharmaceuticals, Inc. (SCMP) Scheduled to Post Quarterly Earnings on Tuesday
www.americanbankingnews.com - October 31 at 2:50 AM
Sucampo Announces Third Quarter 2017 Earnings CallSucampo Announces Third Quarter 2017 Earnings Call
finance.yahoo.com - October 24 at 9:43 AM
Zacks: Brokerages Anticipate Sucampo Pharmaceuticals, Inc. (SCMP) Will Post Quarterly Sales of $57.44 MillionZacks: Brokerages Anticipate Sucampo Pharmaceuticals, Inc. (SCMP) Will Post Quarterly Sales of $57.44 Million
www.americanbankingnews.com - October 19 at 11:42 AM
ETFs with exposure to Sucampo Pharmaceuticals, Inc. : October 17, 2017ETFs with exposure to Sucampo Pharmaceuticals, Inc. : October 17, 2017
finance.yahoo.com - October 17 at 3:41 PM
Sucampo Pharmaceuticals, Inc. (SCMP) Rating Increased to Buy at Zacks Investment ResearchSucampo Pharmaceuticals, Inc. (SCMP) Rating Increased to Buy at Zacks Investment Research
www.americanbankingnews.com - October 17 at 12:56 PM
Zacks: Brokerages Anticipate Sucampo Pharmaceuticals, Inc. (SCMP) to Post $0.25 EPSZacks: Brokerages Anticipate Sucampo Pharmaceuticals, Inc. (SCMP) to Post $0.25 EPS
www.americanbankingnews.com - October 17 at 10:30 AM
Sucampo Pharmaceuticals, Inc. (SCMP) Price Target Lowered to $15.00 at UBS AGSucampo Pharmaceuticals, Inc. (SCMP) Price Target Lowered to $15.00 at UBS AG
www.americanbankingnews.com - October 14 at 10:12 PM
Sucampo Pharmaceuticals, Inc. (SCMP) Given Consensus Rating of "Buy" by BrokeragesSucampo Pharmaceuticals, Inc. (SCMP) Given Consensus Rating of "Buy" by Brokerages
www.americanbankingnews.com - October 12 at 4:44 AM
ETFs with exposure to Sucampo Pharmaceuticals, Inc. : October 6, 2017ETFs with exposure to Sucampo Pharmaceuticals, Inc. : October 6, 2017
finance.yahoo.com - October 7 at 8:16 AM
FY2020 Earnings Estimate for Sucampo Pharmaceuticals, Inc. (SCMP) Issued By Leerink SwannFY2020 Earnings Estimate for Sucampo Pharmaceuticals, Inc. (SCMP) Issued By Leerink Swann
www.americanbankingnews.com - October 6 at 2:50 PM
Financial Analysis: Sucampo Pharmaceuticals (SCMP) versus Its PeersFinancial Analysis: Sucampo Pharmaceuticals (SCMP) versus Its Peers
www.americanbankingnews.com - October 6 at 10:16 AM
Sucampo Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : SCMP-US : October 4, 2017Sucampo Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : SCMP-US : October 4, 2017
finance.yahoo.com - October 6 at 9:01 AM
Sucampo Pharmaceuticals Announces FDA Acceptance of sNDA for AMITIZA in Children with Pediatric Functional Constipation, with Priority Review DesignationSucampo Pharmaceuticals Announces FDA Acceptance of sNDA for AMITIZA in Children with Pediatric Functional Constipation, with Priority Review Designation
finance.yahoo.com - October 3 at 12:11 PM
Sucampo Pharmaceuticals Inc (SCMP): What Does It Mean For Your Portfolio?Sucampo Pharmaceuticals Inc (SCMP): What Does It Mean For Your Portfolio?
finance.yahoo.com - October 3 at 12:11 PM
Sucampo Pharmaceuticals, Inc. (SCMP) Downgraded by MizuhoSucampo Pharmaceuticals, Inc. (SCMP) Downgraded by Mizuho
www.americanbankingnews.com - October 3 at 8:41 AM
Sucampo Pharmaceuticals Announces FDA Acceptance of sNDA for AMITIZA in Children with Pediatric Functional ... - GlobeNewswire (press release)Sucampo Pharmaceuticals Announces FDA Acceptance of sNDA for AMITIZA in Children with Pediatric Functional ... - GlobeNewswire (press release)
globenewswire.com - September 30 at 11:40 PM
Sucampo (SCMP) Reports FDA Acceptance of sNDA for AMITIZA in Children with Pediatric Functional Constipation, with Priority Review DesignationSucampo (SCMP) Reports FDA Acceptance of sNDA for AMITIZA in Children with Pediatric Functional Constipation, with Priority Review Designation
www.streetinsider.com - September 28 at 8:13 PM
Sucampo Pharmaceuticals Announces Presentation at Deutsche Bank’s 25th Annual Leveraged Finance ConferenceSucampo Pharmaceuticals Announces Presentation at Deutsche Bank’s 25th Annual Leveraged Finance Conference
www.nasdaq.com - September 27 at 10:58 PM
Sucampo Pharmaceuticals Announces Presentation at Deutsche Banks 25th Annual Leveraged Finance ConferenceSucampo Pharmaceuticals Announces Presentation at Deutsche Bank's 25th Annual Leveraged Finance Conference
feeds.benzinga.com - September 27 at 10:33 PM
Drug Makers Stock Performance Review -- Apricus Biosciences, DURECT, Sucampo Pharma, and DepomedDrug Makers Stock Performance Review -- Apricus Biosciences, DURECT, Sucampo Pharma, and Depomed
www.bizjournals.com - September 27 at 5:56 PM
Sucampo (SCMP) Presents At Cantor Fitzgerald Global Healthcare Conference - SlideshowSucampo (SCMP) Presents At Cantor Fitzgerald Global Healthcare Conference - Slideshow
seekingalpha.com - September 27 at 5:56 PM
Drug Makers Stock Performance Review -- Apricus Biosciences, DURECT, Sucampo Pharma, and Depomed - PR Newswire (press release)Drug Makers Stock Performance Review -- Apricus Biosciences, DURECT, Sucampo Pharma, and Depomed - PR Newswire (press release)
www.prnewswire.com - September 26 at 3:31 PM
Sucampo Pharmaceuticals Appoints Alex Driggs as General CounselSucampo Pharmaceuticals Appoints Alex Driggs as General Counsel
finance.yahoo.com - September 23 at 5:30 AM
Sucampo Pharmaceuticals Announces Webcast of Its Presentation at the 2017 Leerink Partners Roundtable Series: Rare Disease & Immuno-OncologySucampo Pharmaceuticals Announces Webcast of Its Presentation at the 2017 Leerink Partners Roundtable Series: Rare Disease & Immuno-Oncology
finance.yahoo.com - September 23 at 5:30 AM
Sucampo Pharmaceuticals Announces Webcast of Its Presentation at the 2017 Cantor Fitzgerald Global Healthcare ConferenceSucampo Pharmaceuticals Announces Webcast of Its Presentation at the 2017 Cantor Fitzgerald Global Healthcare Conference
finance.yahoo.com - September 20 at 8:47 AM
Sucampo Pharmaceuticals, Inc. (SCMP) Receives Consensus Recommendation of "Buy" from BrokeragesSucampo Pharmaceuticals, Inc. (SCMP) Receives Consensus Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - September 17 at 4:40 AM

Social Media

Financials

Chart

Sucampo Pharmaceuticals (NASDAQ SCMP) Chart for Wednesday, November, 22, 2017
Loading chart…

This page was last updated on 11/22/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.